Back

Introduction - SGLT2 inhibition in the management of CV risk & T2DM: ask the experts.

28 August 2016 (15:45 - 15:50)
Organised by:
Congress Presentation Part of: SGLT2 inhibition in the management of CV risk & T2DM: ask the experts Diabetes management ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)

2 More presentations in this session

Presentation thumbnail
SGLT-2 inhibitors in the management of CVD and T2DM: brief update on results of the EMPA-REG OUTCOME trial.
Professor S. Inzucchi (New Haven, US)
Presentation thumbnail
Interactive discussion: what are the implications of SGLT2 inhibition for CV risk reduction in a multi-risk patient population?
Professor J. Deanfield (London, GB) Professor S. Inzucchi (New Haven, US)

Access the full session

Session thumbnail
SGLT2 inhibition in the management of CV risk & T2DM: ask the experts

The Event

Event poster

ESC Congress 2016

28 August 2016 15:45 CET
You may be interested in
thumbnail
Congress Presentation
Novel multidisciplinary cardiometabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation
27 August 2021
thumbnail
Webinar
Early initiation of SGLT-2 inhibitors after acute decompensated heart failure
26 October 2022
thumbnail
Congress Presentation
Panel discussion - FIDELITY.
29 August 2022
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources